🔗 Share this article

While the United States proceeds with historic adjustments to its vaccination guidelines, an unexpected name appears somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who first made her name by casting doubt on Covid shots throughout the pandemic and has focused upon possible fatalities following COVID-19 immunization in her short position at the Food and Drug Administration.

Proposed Shifts to Pediatric Vaccine Schedule

Agency leaders had intended to unveil major changes to the pediatric vaccination calendar in December, aligning the US with Denmark’s vaccine program, it is understood – a major change that would place the US at odds with many the global community with little proof for public health gain. The planned update has been pushed back until the new year.

In place of the director of the vaccine center, Tracy Beth Høeg is set to present at the gathering. She was newly appointed interim head of the FDA’s CDER, the fifth individual to head the center this year.

A New Direction at the Agency

This interim role may indicate a tighter collaboration between the drug and biologics branches as Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it suggests a greater focus upon rolling back previously authorized immunizations at the FDA.

The new acting director has often pushed for halting some childhood vaccine recommendations in the US in order to be more in line with the Danish model, a country with universal health coverage and a number of inhabitants about the size of Wisconsin’s.

To date statements, she has continued to focus on immunizations – typically the responsibility of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to medication approval.

Concerns Over Expertise

Høeg has no apparent experience in pharmaceutical research, oversight or management, which has been typical for previous directors of the CBER. She has worked at the FDA as a senior adviser to the agency head and CBER since earlier this year.

“It seems she lacks to have the requisite experience” for leading the CDER, said a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She is not versed in leading a large organization. She lacks background in industry regulation.”

Past directors of the center would “understand regulatory frameworks and the science of pharmaceutical innovation”, noted a former acting FDA commissioner. “Frankly, she has not acquired the kind of background that previous people who headed CBER have had.”

This division has an enormous portfolio at the FDA, the former commissioner stated.

“Everybody just pays attention on the new drug program, but the generic program clears a multitude of generic medications. There is also a biologic copycat branch, non-prescription drug unit and so forth, and all of those must be looked after,” Dr. Woodcock explained. “The area you don’t keep your eye on, that’s the thing that I always told people is going to cause problems.”

Furthermore, a significant administrative component to the position, which oversees more than 5,000 employees. “It is a massive administrative position, if you do it right,” the former official said.

Official Statement and Contentious Programs

Regarding inquiries about Høeg’s qualifications and whether this appointment signifies greater collaboration among FDA leaders on immunizations, a press secretary stated that the “questions rely on inaccurate assumptions”.

“Her resume is consistent with the duties of her position,” the spokesperson stated, noting the period Dr. Høeg spent advising the FDA commissioner on “drug safety and approval science, including computerized risk analysis and immunization monitoring”.

In her interim role, Dr. Høeg inherits the commissioner’s recently launched expedited review system, a controversial rapid drug-approval program that reportedly concerned her preceding directors. “How are these medications being chosen for this expedited pathway? Who makes the decisions?” Dr. Howard asked. “There is a lot of secrecy happening at the agency right now.”

In general, he remarked, “the Food and Drug Administration seems to be moving towards less stringent oversight of all drugs, except for immunizations.”

Established Track Record on Vaccines

With immunizations, Høeg has a more established, if troubling, history, Howard said. She authored a study using non-validated public submissions to assess the rate of heart inflammation following Covid vaccination. She advised the state of Florida surgeon general Joseph Ladapo, who reportedly have modified findings to indicate Covid vaccinations are more dangerous than they are.

Included in her “wish list” for the current government featured changing rules for novel immunizations and ending “unnecessary” vaccines, she said post-election on a audio program. At the agency, Dr. Høeg has according to sources floated the idea of barring adolescent males from getting Covid vaccines.

“She’s an all-around true believer who starts off with her conclusions and works backwards to retrofit the evidence in a very disingenuous, untruthful fashion,” Dr. Howard said.

Consolidating Power and a “Push for Payback”

Høeg aligned with other skeptics, {like|